disease 1,609 words KG: ent-dise-01761651 2026-03-23
kind:diseasesection:diseasesstate:published
Contents

LATE (Limbic-Predominant Age-Related TDP-43 Encephalopathy)

Disease Info
TDP-43 PathologyPhosphorylated, ubiquitinated, and truncated TDP-43 inclusions
Limbic PredominancePrimary involvement of amygdala, hippocampus, and entorhinal cortex
Age AssociationTypically onset after age 80
Clinical PhenotypeAmnestic syndrome resembling AD but with distinct progression
Age 70-79Approximately 5-10% prevalence
Age 80-89Approximately 15-20% prevalence
Age 90+Up to 25-30% prevalence in some cohorts
DatabasesOMIMOrphanetClinicalTrialsPubMed

Knowledge Graph

Related Hypotheses (12)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51

Related Analyses (7)

Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived

Related Experiments (8)

Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40